Result of EGM

RNS Number : 4691I
Oxford Biomedica PLC
25 July 2012
 

FOR IMMEDIATE RELEASE

25 July 2012

                                               

OXFORD BIOMEDICA PLC

GENERAL MEETING

 

Oxford, UK - 25 July 2012: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, announced today that all resolutions proposed were duly passed at its General Meeting, held today in London.

 

In accordance with Listing Rule 9.6.18, the following resolution passed at the meeting concerned special business:

 

·      Resolution 2: to empower the Directors to allot equity securities for cash, pursuant to section 570 of the Act as if section 561 of the Act did not apply to such allotment, up to an aggregate nominal amount of £6,410,373.53.

 

The full text of all the resolutions can be viewed in the Notice of Meeting by visiting the Company's website at www.oxfordbiomedica.co.uk (located on pages 143 to 145 of the prospectus dated 6 July 2012).

 

Certified copies of the document setting out the above resolutions passed at this General Meeting have been submitted to the National Storage Mechanism and will shortly be available for inspection at: www.Hemscott.com/nsm.do.

 

The results of the proxy voting in advance of the meeting are shown below.

 

 

 

Resolution

 

Votes 

For

Votes at 

Chairman's

Discretion

Votes at 

other proxy

Discretion

 

 Votes

Against

 

Votes 

Withheld

 

Total

votes cast

Result









Ordinary resolution






1

435,386,160

607,230

1,441,423

251,913

40,343

437,727,069

Passed









Special resolution






2

435,168,275

599,040

1,441,423

339,017

179,314

437,727,069

Passed









Ordinary resolution






3

435,324,264

602,092

1,441,423

255,979

103,311

437,727,069

Passed









 

-Ends-

 

For further information, please contact:

 

Oxford BioMedica plc:

Lara Mott, Head of Corporate Communications

Tel: +44 (0)1865 783 000

 

Media Enquiries:

Mary Clark/Sarah Macleod/Claire Dickinson

M:Communications

 

Tel: +44 (0)20 7920 2360

 

 

Notes to editors

 

1. Oxford BioMedica

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs.  The Company's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy.  Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions and ImaginAb.  Further information is available at www.oxfordbiomedica.co.uk.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 

END

 
 

REGSELFSIFESEDW